Sopit Wongkham

Khon Kaen, Thailand

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 171 publications

Glucosamine induces apoptosis of cholangiocarcinoma cells by suppressing high-mannose type N-glycosylation and EGFR/STAT3 signaling.

Glucosamine induces apoptosis of cholangiocarcinoma cells by suppressing high-mannose type N-glycosylation and EGFR/STAT3 signaling.

Journal: Future science OA
Published: March 09, 2026

HMGA1 is associated with unfavorable outcome and accelerates the aggressiveness of cholangiocarcinoma.

HMGA1 is associated with unfavorable outcome and accelerates the aggressiveness of cholangiocarcinoma.

Journal: SAGE open medicine
Published: February 18, 2026

Preoperative Glucose-Lymphocyte Ratio: A New Potential Prognostic Marker for Patients with Cholangiocarcinoma.

Preoperative Glucose-Lymphocyte Ratio: A New Potential Prognostic Marker for Patients with Cholangiocarcinoma.

Journal: Nutrition and cancer
Published: August 31, 2025

High glucose enhances lung cancer cell aggressiveness: the impacts of GLUT1, UAP1, UGP2, and N-linked glycosylation.

High glucose enhances lung cancer cell aggressiveness: the impacts of GLUT1, UAP1, UGP2, and N-linked glycosylation.

Journal: Glycobiology
Published: August 01, 2025

Asparagine-linked glycosylation protein 1 (ALG1) promotes aggressive phenotypes of lung adenocarcinoma cells, A549, via modulating N-linked glycosylation and ER-Stress.

Asparagine-linked glycosylation protein 1 (ALG1) promotes aggressive phenotypes of lung adenocarcinoma cells, A549, via modulating N-linked glycosylation and ER-Stress.

Journal: Glycoconjugate journal
Published: June 26, 2025

Integrated transcriptomic and molecular docking analysis identifies Rhotekin 2 as a promising therapeutic target for overcoming gemcitabine resistance in cholangiocarcinoma.

Integrated transcriptomic and molecular docking analysis identifies Rhotekin 2 as a promising therapeutic target for overcoming gemcitabine resistance in cholangiocarcinoma.

Journal: Biomedical reports
Published: June 17, 2025

Molecular Mechanisms of Gemcitabine Resistance in Cholangiocarcinoma.

Molecular Mechanisms of Gemcitabine Resistance in Cholangiocarcinoma.

Journal: Oncology research
Published: June 12, 2025

Pro-Tumorigenic Roles of Cyclin Dependent Kinase 2 and its Associated Cyclins in Cholangiocarcinoma Progression under High Glucose Condition.

Pro-Tumorigenic Roles of Cyclin Dependent Kinase 2 and its Associated Cyclins in Cholangiocarcinoma Progression under High Glucose Condition.

Journal: Archives of medical research
Published: May 14, 2025

Cholangiocarcinoma-derived secreted products and growth arrest-specific 2-like 3 enhance migratory and invasive abilities of fibroblasts.

Cholangiocarcinoma-derived secreted products and growth arrest-specific 2-like 3 enhance migratory and invasive abilities of fibroblasts.

Journal: European journal of cell biology
Published: February 19, 2025

Silencing of O-GlcNAc Transferase Attenuated O-GlcNAcylation and Metastatic Potentials of Melanoma Cells Through Suppression of Akt-NFκB Signaling Pathway.

Silencing of O-GlcNAc Transferase Attenuated O-GlcNAcylation and Metastatic Potentials of Melanoma Cells Through Suppression of Akt-NFκB Signaling Pathway.

Journal: Chembiochem : a European journal of chemical biology
Published: October 29, 2024

Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma.

Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma.

Journal: Anticancer research
Published: October 03, 2024

Development of a monomeric recombinant Butea monosperma agglutinin as a diagnostic and prognostic biomarker for cholangiocarcinoma.

Development of a monomeric recombinant Butea monosperma agglutinin as a diagnostic and prognostic biomarker for cholangiocarcinoma.

Journal: Biochimica et biophysica acta. General subjects
Published: October 01, 2024
Showing 1-12 of 171

Last Updated: 09/26/2026